Drug Profile
Research programme: hepatitis C virus replication inhibitors - Presidio Pharmaceuticals/Stanford University
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Stanford University
- Class
- Mechanism of Action Hepatitis C virus replication inhibitors; Viral nonstructural protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA
- 22 Jan 2007 Preclinical trials in Hepatitis C in USA (unspecified route)